NICEATM

National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods

ICCVAM

Interagency Coordinating Committee on the Validation of Alternative Methods



The Murine Local Lymph Node Assay: 5-Bromo-2-deoxyuridine Enzyme-linked Immunosorbent Assay (LLNA: BrdU-ELISA)

> Judy Strickland, Ph.D., DABT ILS Inc., Contractor Supporting NICEATM

ICCVAM Workshop Series on Best Practices for Regulatory Safety Testing: Assessing the Potential for Chemically Induced Allergic Contact Dermatitis

January 20, 2011

William H. Natcher Conference Center National Institutes of Health Bethesda, MD










Overview of the LLNA: BrdU-ELISA


- Developed by Takeyoshi et al. as a nonradioactive LLNA¹
- Measures BrdU incorporation in draining auricular lymph nodes as a measure of lymph node cell proliferation
 - BrdU is a thymidine analog, incorporated into proliferating cell DNA in a manner similar to radioisotope incorporation in the LLNA
 - ELISA detects peroxidase-labeled BrdU antibody
 - Colorimetric reaction measured with a plate reader

¹Takeyoshi et al. 2001. Toxicol Lett. 119:203-8.

LLNA Test Method Protocol




LLNA: BrdU-ELISA Test Method Protocol - 1



LLNA: BrdU-ELISA Test Method Protocol - 2

- Lymphocyte suspension
 - Crush lymph nodes
 - Pass through #70 nylon mesh
 - Suspend lymph node cells in 15 mL physiological saline
 - (return to webpage to view Cell Suspension video clip)





Video courtesy of Dr. Takeyoshi – CERI, Japan



LLNA: BrdU-ELISA Test Method Protocol - 3

- Sample Processing
 - 100 µl cell suspension added to flat-bottom microplate wells
 - Centrifuge (300 x g, 10 minutes)
 - Remove supernatants and dry
 - (return to webpage to view Supernatant Removal video clip)



Video courtesy of Dr. Takeyoshi – CERI, Japan



LLNA: BrdU-ELISA Test Method Protocol – ICCVAM Recommendations - 1

- $SI \ge 1.6$ decision criterion
- Minimum of four animals per group
- Individual animal data
 - Allows for statistical analysis for detection of outliers and comparison to vehicle control group
- Concurrent vehicle control
 - Used as the baseline to determine any increase in lymphocyte proliferation of treated animals
- Concurrent positive control
 - Demonstrates that the assay as conducted is capable of producing a positive response
 - Required by U.S. agencies
 - Absence of a concurrent positive control could result in a requirement to repeat negative results

LLNA: BrdU-ELISA Test Method Protocol – ICCVAM Recommendations - 2

- Dose selection with adequate scientific rationale
 - Select 3 consecutive doses from an appropriate concentration series (100%, 50%, 25%, 10%, 5%, 2.5%, 1%, 0.5%, etc.)
 - Consider existing toxicological information (acute toxicity, dermal irritation)
 - Consider structural and physicochemical information on test material or structurally related test material
 - In absence of such existing information a prescreen test may be necessary
- Reduced LLNA: BrdU-ELISA
 - Should be used routinely to determine the allergic contact dermatitis (ACD) hazard potential of chemicals and products
 - If existing information suggests a substance might have ACD hazard potential AND dose-response information is needed, consider testing in the multi-dose LLNA: BrdU-ELISA
 - Reduces animal numbers by using only the high dose group
 - Maximum concentration that doesn't induce overt systemic toxicity and/or excessive local skin irritation
 - Adhere to all other LLNA: BrdU-ELISA protocol specifications

Advantages of Using the LLNA: BrdU-ELISA

- Less hazardous, no radioisotopes
 - Makes LLNA available to laboratories where radioactivity is discouraged/prohibited
 - Refinement: avoids potential pain and distress associated with a positive response in guinea pig tests
 - Avoids costs associated with radioactive waste
- Reduction vs. guinea pig tests
 - Four mice per dose group
- Convenient and rapid assay
 - Commercially available reagent kits
- Training and time considerations are similar to LLNA

NICEATM-ICCVAM Evaluation of LLNA: BrdU-ELISA

- Reviewed available data and information regarding the usefulness and limitations to assess the ACD hazard potential of chemicals and products
- Determined validation status
 - Accuracy: sensitivity and specificity
 - Reproducibility for identifying LLNA sensitizers and nonsensitizers
 - Scope of substances tested
 - Availability of a standardized test method protocol
- Independent international scientific peer review panel

NICEATM-ICCVAM Evaluation of LLNA: BrdU-ELISA – Validation Database - 1

- 47 total substances; 43 with comparative traditional LLNA data
- Intralaboratory data
 - Individual animal data for 12 substances tested 2 to 6 times in one laboratory¹⁻⁷
- Interlaboratory data
 - Individual animal data from Phase II of the Japanese Society for Alternative Animal Experiments (JSAAE) validation study⁸
 - 10 coded substances tested in three to seven laboratories
 - 4/10 substances not previously tested in the LLNA: BrdU-ELISA

¹Takeyoshi et al. 2003. Toxicology. 191:259-263; ²Takeyoshi et al. 2004. Exp Anim 53:171-173; ³Takeyoshi et al. 2005. J Appl Toxicol 25:129-134; ⁴Takeyoshi et al. 2006. J Appl Toxicol 26:5-9; ⁵Takeyoshi et al. 2007. 6th World Congress Presentation; ⁶Takeyoshi et al. 2008. J Appl Toxicol 28:530-534; ⁷Takeyoshi et al. unpublished data; ⁸Kojima et al. 2011. J Appl Toxicol 31: 63-74

NICEATM-ICCVAM Evaluation of LLNA: BrdU-ELISA – Validation Database - 2

- Test method reference substances (n = 43)
 - Includes 16/18 required (and 2/4 optional) LLNA performance standards reference substances

Trad	Traditional LLNA Nonsensitizers (n = 11)		
3-Aminophenol	Diethyl maleate	Imidazolidinyl urea	Diethyl phthalate
Aniline	2,4-	Isoeugenol	Dimethyl isophthalate
Benzoquinone	Dinitrochlorobenzene	Isopropyl myristate	Glycerol
4-Chloroaniline	Diphenylcyclopropenone		Hexane
5-Chloro-2-methyl-4-	Ethyl acrylate	2-Mercaptobenzothiazole	2-Hydroxypropyl
isothiazolin-3-one	Ethylene glycol	4-Methylaminophenol	methacrylate
Cinnamic alcohol	dimethacrylate	sulfate	Isopropanol
Cinnamic aldehyde	Eugenol	Nickel sulfate	Lactic acid
<i>trans</i> -Cinnamic	Formaldehyde	Phenyl benzoate	Methyl salicylate
aldehyde	Glutaraldehyde	4-Phenylenediamine	Propylene glycol
Citral Cobalt chloride Cyclamen aldehyde	Hexyl cinnamic aldehyde Hydroxycitronellal	Sodium lauryl sulfate Trimellitic anhydride	Salicylic acid Sulfanilamide

Abbreviations: n = number of substances.

Bold type = LLNA performance standards reference substance.

NICEATM-ICCVAM Evaluation of LLNA: BrdU-ELISA – Test Method Accuracy - 1

LLNA: BrdU-ELISA vs. LLNA (n = 43)


SI Decisio n Criterion	n	Accuracy	Sensitivity	Specificity	False Positive Rate	False Negative Rate	Positive Predictivity	Negative Predictivity
≥2.0	43	95% (41/43)	94% (30/32)	100% (11/11)	0% (0/11)	6% (2/32)	100% (30/30)	85% (11/13)
≥1.8	43	91% (39/43)	94% (30/32)	82% (9/11)	18% (2/11)	6% (2/32)	94% (30/32)	82% (9/11)
≥1.6	43	95% (41/43)	100% (32/32)	82% (9/11)	18% (2/11)	0% (0/32)	94% (32/34)	100% (9/9)
≥1.4	43	93% (40/43)	100% (32/32)	73% (8/11)	27% (3/11)	0% (0/32)	91% (32/35)	100% (8/8)

Abbreviations: n = number of substances; SI = stimulation index



13

NICEATM-ICCVAM Evaluation of LLNA: BrdU-ELISA – Test Method Accuracy - 2



NICEATM-ICCVAM Evaluation of LLNA: BrdU-ELISA – Intralaboratory Reproducibility

- Individual animal data for 12 substances tested (2-6 times) in one laboratory¹⁻⁷
 - 10/12 substances were LLNA sensitizers
 - Repeat positive LLNA: BrdU-ELISA results (SI \geq 1.6) for 8/10 LLNA sensitizers
 - One positive LLNA: BrdU-ELISA result (SI \geq 1.6) and one negative LLNA: BrdU-ELISA result (SI < 1.6) for 2/10 LLNA sensitizers
 - 2/12 substances were LLNA nonsensitizers
 - Repeat negative LLNA: BrdU-ELISA results (SI < 1.6) for 1/2 LLNA nonsensitizers
 - Repeat positive LLNA: BrdU-ELISA results (SI \geq 1.6) for 1/2 LLNA nonsensitizers

¹Takeyoshi et al. 2003. Toxicology. 191:259-263; ²Takeyoshi et al. 2004. Exp Anim 53:171-173; ³Takeyoshi et al. 2005. J Appl Toxicol 25:129-134; ⁴Takeyoshi et al. 2006. J Appl Toxicol 26:5-9; ⁵Takeyoshi et al. 2007. 6th World Congress Presentation; ⁶Takeyoshi et al. 2008. J Appl Toxicol 28:530-534; ⁷Takeyoshi et al. unpublished data. **ICCVAM**

15

NICEATM-ICCVAM Evaluation of LLNA: BrdU-ELISA – Interlaboratory Reproducibility

- Individual animal data from Phase II of the JSAAE validation study¹
 - 10 coded substances tested in three to seven laboratories
 - 7/10 substances were LLNA sensitizers
 - 3/10 substances were LLNA nonsensitizers
 - Concordant results for 9/10 substances among all the laboratories tested
 - One LLNA nonsensitizer with concordant positive LLNA: BrdU-ELISA results (SI ≥ 1.6)
 - Discordant results for 1/10 substances among 2/7 laboratories tested
 - Substance was an LLNA nonsensitizer
 - LLNA: BrdU-ELISA results were positive (SI ≥ 1.6) in two laboratories and negative (SI < 1.6) in 5 laboratories

¹Kojima et al. 2011. J Appl Toxicol 31: 63-74

ICCVAM Test Method Recommendations for LLNA: BrdU-ELISA – Usefulness and Limitations

<u>Usefulness</u>

- Can be used to identify potential skin sensitizers or nonsensitizers
 - Use SI \geq 1.6 to identify potential sensitizers
 - Produced no false negatives, relative to traditional LLNA

Limitations

- Borderline weak positives (1.6 < SI < 1.9) have a slight potential to be false positives
 - If not consistent with predicted ACD hazard potential, consider all other available information
 - Nature of dose response
 - Evidence of systemic toxicity and/or excessive local skin irritation
 - Where appropriate, statistical significance
 - Structural relationship to known skin sensitizers
- Same limitations as those associated with LLNA applicability domain except for nickel

LLNA: BrdU-ELISA International Acceptance

- OECD TG 442B Skin Sensitization: Local Lymph Node Assay: BrdU-ELISA
 - Adopted July 22, 2010
 - Available at <u>http://www.oecd-</u> <u>ilibrary.org/environment/test-no-442b-skin-</u> <u>sensitization_9789264090996-en</u>
 - Based on ICCVAM-recommended LLNA: BrdU-ELISA protocol
 - Expected to result in broader use of LLNA tests, which will further reduce and refine animal use for ACD hazard assessments on a global basis, while ensuring human safety



Poster Available for Viewing

 See poster at this workshop (Room C1/C2):
ICCVAM Evaluation and International Acceptance of the Nonradioactive LLNA: BrdU-ELISA Test Method
A Jacobs¹, J Matheson², M Wind², V Malshet¹, J Toy¹, J Strickland³, D Allen³, T Burns³, F Stack³, W Stokes⁴
¹U.S. FDA, Silver Spring, MD; ²U.S. CPSC, Bethesda, MD;
³ILS, Inc., Contractor Supporting NICEATM, RTP, NC;
⁴NICEATM/NTP/NIEHS/NIH/DHHS, RTP, NC

Acknowledgements

 ICCVAM and NICEATM gratefully acknowledge the following individuals and institutions for submitting data to NICEATM for the LLNA: BrdU-ELISA evaluation

Masahiro Takeyoshi, Ph.D.	Hajime Kojima, Ph.D.			
Chemicals Evaluation and Research Institute	Japanese Center for the Validation of Alternative Methods			
Saitama, Japan	National Institute of Health Sciences			
	Ministry of Health, Labour and Welfare			
	Tokyo, Japan			

Additional Acknowledgements

- ICCVAM
- ICCVAM Interagency Immunotoxicity Working Group
- ICCVAM Independent Scientific Peer Review Panel
- NICEATM Staff